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doi:10.1016/j.jtcvs.2003.11.015Objective: Accumulation of smooth muscle cells and extracellular matrix in the
intima of artery bypass grafts induces neointimal hyperplasia, resulting in graft
failure. We investigated the inhibitory effect of locally applied cilostazol, an
inhibitor of cyclic adenosine monophosphate phosphodiesterase III, on neointimal
hyperplasia and the role of tenascin-C synthesis and smooth muscle cell prolifera-
tion in free artery grafts.
Methods and Results: We established a distal anastomotic stricture model of free
artery graft stenosis using rat abdominal aorta. In this model, neointimal hyperplasia
was observed not only in the distal anastomotic site but also in the graft body at
postoperative day 14 and was markedly progressed at day 28. Strong expression of
tenascin-C was found in the media and neointima of the graft body. When cilostazol
was locally administered around the graft using Pluronic gel, neointimal hyperplasia
of the graft was significantly suppressed in comparison with gel-treated control
graft. The mean neointima/media area ratio was reduced by 86.6% for the graft body
and by 75.8% for the distal anastomotic site versus the control. Cilostazol treatment
decreased cell proliferation and tenascin-C expression in the neointima. In an in
vitro experiment using cultured smooth muscle cells isolated from rat aorta, cilosta-
zol completely suppressed the tenascin-C mRNA expression induced by platelet-
derived growth factor-BB.
Conclusion: A single topical administration of cilostazol may suppress neointimal
hyperplasia by inhibiting cell proliferation and tenascin-C synthesis in free artery
grafts, presenting the potential for clinical use in vascular surgery.
One of the most serious problems in coronary artery bypass graftingis stenosis at the site of anastomosis, which induces neointimalformation and eventually results in occlusion of the artery graft.Similar to arteriosclerosis, the primary pathophysiologic eventassociated with neointimal formation is migration of smoothmuscle cells (SMCs) from the media to the intima.1,2 The SMCs
then proliferate and deposit extracellular matrix (ECM), leading to the formation of
an occlusive lesion.3-5 It has recently been suggested that tenascin-C (TN-C), an
ECM protein, may play a crucial role in the remodeling of cardiovascular tissue by
affecting cell activity.4-9 Marked expression of TN-C has been found in rat balloon-
10 6injured artery, human coronary atherosclerotic plaque, abdominal aortic aneu-
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CSPrysm,11 and arterialized human vein grafts,12 as well as in
the early stage after percutaneous transluminal coronary
angioplasty.13 In vitro, TN-C blocks adhesion of SMC to
fibronectin14 and promotes migration.15 Platelet-derived
growth factor (PDGF) and angiotensin II markedly up-
regulate the synthesis of TN-C by cultured SMC.14,16
A recent report described how locally applied suramin, a
growth factor receptor antagonist, inhibited neointimal hy-
perplasia of mouse vein grafts.17 Local administration of
phosphodiesterase inhibitors also inhibits neointimal forma-
tion in balloon-injured carotid artery by inhibiting medial
SMC proliferation.18,19 Local application of a drug is an
attractive and feasible therapy in bypass surgery with few
side effects.
Cilostazol, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-
3,4-dihydro-2(1H)-quinolinone, is a specific inhibitor of
cyclic adenosine monophosphate (cAMP) phosphodiester-
ase III that inhibits platelet aggregation and SMC prolifer-
20-22
Figure 1. Elastica van Gieson-stained cross sections (B-D and
E-F) and immunostaining for TN-C (H-J) of artery grafts (magnifi-
cation 40). A, Diagram of implanted grafts indicating sections
examined. B-D, Distal anastomotic stricture site. E-J, Graft body.
B, E, H, POD 7. C, F, I, POD 14. D, G, J, POD 28. Arrows indicate
internal elastic lamina. POD, Postoperative day.ation and produces vasodilatation. In this study, we
358 The Journal of Thoracic and Cardiovascular Surgery ● Septinvestigated whether a single local administration of cilosta-
zol is capable of suppressing neointimal hyperplasia in
implanted artery grafts. Furthermore, we also evaluated the
effects of cilostazol on TN-C expression and SMC prolif-
eration.
Materials and Methods
Rat Anastomotic Stricture Model of Free Artery Graft
Stenosis
Male inbred Lewis rats with a mean body weight of 270 g were
used. The animals were handled according to guidelines approved
by the Mie University Animal Experiment and Care Committee.
The rats were anesthetized by intraperitoneal injection of sodium
pentobarbital (50 mg/kg) and atropine (0.1 mg). Using a sterile
technique, we exposed the aorta below the renal artery through an
abdominal incision. A 2.0-cm segment of infrarenal aorta was
removed from the donor rat. Recipient rats were given an identical
abdominal incision. After an injection of 100 U/kg of heparin into
the right lumbar vein, the abdominal aorta was clamped between
the renal arteries and the bifurcation of the aorta and then dis-
sected. The donor aortic segment was transplanted into the recip-
ient aorta in an end-to-end fashion. Anastomosis was performed by
interrupted 10-0 nylon sutures. In the stricture group, distal anas-
tomotic stricture was experimentally produced by ligating the
distal anastomosis with a 22-gauge catheter (outer diameter 0.7
mm) using 1-0 silk thread and then removing it. In the control
group, the operation was performed without aortic constriction. In
the cilostazol-treated group, rats with the anastomotic stricture
received 20 mg of cilostazol dissolved in 200 L of dimethyl
sulfoxide containing 25% Pluronic gel locally by topical applica-
tion around the interposed graft, as previously described.18 Rats in
the vehicle-treated group received the same dimethyl sulfoxide-
Pluronic gel without cilostazol.
Graft Harvesting and Morphometric Analysis
Artery grafts were harvested at 7, 14, and 28 days after surgery
(6-8 rats per group at each time point) under anesthesia. Recipient
rats were perfused with 100 mL of heparin-prepared saline fol-
lowed by 100 mL of 10% neutral-buffered formalin solution. The
grafts were exposed carefully and extracted, including proximal
and distal normal aorta, and then postfixed in the same fixative at
4°C for 1 to 2 days and embedded in paraffin. For histologic
analysis of the graft body, 5 cross sections (4 m thick) were cut
from the mid-portion between the distal anastomosis and the center
of the graft (Figure 1, A). Four cross sections were selected from
the distal anastomotic site (Figure 1, A) and stained with elastica
van Gieson to demarcate the internal elastic lamina. At each
section, the ratio between the neointima and the media was calcu-
lated using an image analysis system (Adobe Photoshop version
5.0J and NIH Image version 1.61, Macintosh; Adobe Systems, Inc,
San Jose, Calif) as previously described.19
Immunohistochemical Analysis
Immunohistochemical staining for TN-C was performed according
to the method previously reported.23 In brief, the sections were
first incubated with mouse monoclonal anti-rat TN-C antibody (1
g/mL) and then with peroxidase-conjugated anti-mouse immu-
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Pnoglobulin G (1:400, MBL, Nagoya, Japan). The sections were
treated with diaminobenzidine/H2O2 solution and counterstained
with hematoxylin.
To identify the cellular source of the neointima, immunohisto-
chemical staining for -smooth muscle actin (SMA) was per-
formed using peroxidase-conjugated anti--SMA antibody
(DAKO, Tokyo, Japan). In addition, to assess the differentiation
and proliferation of SMCs, immunohistochemical staining for pro-
liferating cell nuclear antigen (PCNA) was performed using mouse
monoclonal antibody against PCNA (PC10, DAKO, Tokyo, Ja-
pan), followed by the immunoperoxidase procedure. PCNA index
was determined by dividing the number of PCNA-positive cells by
the total number of nucleated cells in the neointima and media
from each section.
In Situ Hybridization
TN-C mRNA expression was detected by in situ hybridization at
our laboratory using the method previously reported.24 Rat aortic
tissues were treated with proteinase K for 10 minutes, and hybrid-
ization signals were visualized with alkaline phosphatase-conju-
gated anti-digoxigenin antibody, followed by incubation in nitro-
tetrazolium blue/5-bromo-4-chloro-3-indolyl phosphate solution.
Measurement of Tissue and Plasma Concentrations of
Cilostazol
The rats were killed at 14, 28, and 56 days (4 rats at each time
point) after local administration of cilostazol to measure plasma
and tissue concentrations of the drug. Artery grafts were harvested
and washed in cold phosphate-buffered saline to eliminate any
possible contamination of drug on the surface. The artery grafts
and plasma were stored at 80°C until measurement. Measure-
ment of cilostazol concentrations was performed by high-perfor-
mance liquid chromatography according to the method previously
reported.18
Cell Culture
Rat vascular SMCs were isolated from the thoracic aorta of 10- to
12-week-old male Lewis rats according to the enzyme disperse
method previously reported.16 Cells were grown in Dulbecco’s
modified Eagle’s medium (Sigma, St Louis, Mo) supplemented
with 10% fetal bovine serum, 100 g/mL of streptomycin, and 100
U/mL of penicillin (Gibco BRL, Life Technologies Inc, Rockville,
Md) in a humidified atmosphere (5% CO2/95% air) at 37°C. Cells
between passages 4 and 10 were used for all experiments. SMCs
were grown to confluence in 6 wells and maintained for 48 hours
in a medium containing 0.1% bovine serum albumin and then for
24 hours in 0.1% bovine serum albumin alone or medium con-
taining PDGF-BB (2.5 ng/mL, Sigma) with or without cilostazol
(10 mol/L).
Reverse Transcriptase-Polymerase Chain Reaction
Analysis
Total RNA was isolated from cultured SMCs by the acid guanidine
phenol chloroform method.24 Total RNA concentrations were de-
termined by spectrophotometry at 260 nm. One g of total RNA
template was converted to cDNA using a first-strand cDNA syn-
thesis kit (Roche, Basel, Switzerland). The forward and reverse
primers for TN-C were 5'-GTTTGGAGACCGCAGAGAA-
The Journal of ThoraciGAA-3' and 5'-TGTCCCCATATCTTGCCCATCA-3', respec-
tively. The expected size of this specific polymerase chain reaction
fragment was 344 base pairs. -Actin was used as an internal
control, with forward and reverse primers of 5'-GTGGGGCGC-
CCCAGGCACCA-3' and 5'-CTCCTTAATGTCACGCAC-
GATTTC-3', respectively, and the expected size of the polymerase
chain reaction fragment was 540 base pairs. Images were stored,
and quantitative analysis was performed using an image analysis
system.
Statistical Analysis
Values were expressed as the mean  SD. Statistical analysis
between groups was performed by analysis of variance. When a
statistically significant overall effect was detected, individual data
were compared using the Mann-Whitney test or Bonferroni cor-
rection.
Results
Neointimal Hyperplasia in Rat Artery Grafts
In the stricture group, neointimal hyperplasia was seen in
both the graft body and distal anastomotic site at postoper-
ative day 14 and was markedly progressed at day 28 (Figure
1). Marked neointimal hyperplasia was observed in the graft
body close to the distal anastomotic site, gradually decreas-
ing as it extended to the proximal anastomotic site. There-
fore, for histologic analysis we selected the midportion
between the distal anastomosis and the center of the graft. In
the stricture group, the neointima/media area ratios for the
graft body and the distal anastomotic site at postoperative
day 28 were significantly increased compared with those at
day 14 (Figure 2). The ratios for the graft body and the distal
anastomotic site at postoperative day 28 in the stricture
group were 3 to 4 times higher than those in the non-
stricture group (Figure 2). Immunohistochemical staining
showed a large number of -SMA-positive cells in the
neointima (data not shown).
Expression of TN-C in Rat Artery Grafts
Immunostaining of TN-C was seen in the media at day 7
after grafting. At days 14 and 28, TN-C staining was de-
tected in the neointima of the graft body, whereas the
staining became weaker in the media. TN-C immunolabel-
ing was continuously observed in the adventitia (Figure 1).
In situ hybridization revealed TN-C mRNA-positive
cells in the media and adventitia at day 7. At day 14,
TN-C–expressing cells were observed predominantly in the
neointima (Figure 3). At day 28, the expression of TN-C
mRNA was no longer seen in either the media or the
neointima (data not shown).
Effect of Local Administration of Cilostazol on
Neointimal Hyperplasia and TN-C Expression
In the cilostazol-treated group, neointimal hyperplasia at
day 28 was markedly suppressed in both the graft body and
the distal anastomotic site compared with the vehicle-
c and Cardiovascular Surgery ● Volume 128, Number 3 359
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in the cilostazol-treated group at day 28 were significantly
lower than those in the vehicle-treated group (graft body:
0.055  0.062 vs 0.409  0.172; anastomotic site: 0.089 
0.080 vs 0.368  0.223, P  .05, Figure 5, A and B). The
rate of reduction compared with the vehicle-treated group
was 86.6% for the graft body and 75.8% for the anastomotic
site. These results indicate that a single local administration
of cilostazol significantly suppresses neointimal hyperpla-
sia.
In addition, PCNA indices at day 28 were also signifi-
cantly lower in the cilostazol-treated group than in the
vehicle-treated group (graft body: 3.9%  6.1% vs 37.2%
 9.5%, P  .01; anastomotic site: 19.2%  19.7% vs
39.7%  11.8%, P  .05, Figure 5, C and D). Immunore-
active TN-C in the graft body at day 28 was decreased in the
cilostazol-treated group, being observed only in a small
portion of the media (Figure 4). These results indicate that
local treatment with cilostazol potently inhibits cell prolif-
eration and TN-C expression in the neointima of implanted
Figure 2. Neointima/media area ratio in graft body (A
were selected, and data are mean SD of neointima/m
*Significant difference between PODs 14 and 28 in stric
**Significant difference between stricture and non-
anastomotic site: P < .05). POD, Postoperative day.
Figure 3. Localization of TN-C by in situ hybridization. TN-C
mRNA was detected in the media and adventitia at POD 7 (A), and
predominantly in the neointima at day 14 (B). Arrows indicate
TN-C mRNA-positive cells. Neo, Neointima; med, media; adv,
adventitia.artery grafts, thus suppressing neointimal hyperplasia.
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The plasma concentration of cilostazol was below the de-
tectable level (0.01 g/mL) in all samples. In contrast, the
mean tissue concentration of cilostazol in the artery graft
was 175.44 g/g tissue at 14 days after topical application.
However, the tissue concentration decreased to 0.38 g/g
tissue at day 28 and was below the detectable level at day
distal anastomotic site (B). Four sections per animal
area ratio from 5 animals per group at each time point.
group (graft body: P < .001; anastomotic site: P < .05).
ure groups at POD 28 (graft body: P < .01; distal
Figure 4. Elastica van Gieson–stained cross sections and immu-
nostaining for TN-C of cilostazol-treated graft bodies at POD 28
(magnification 40). A, C, Cilostazol-treated grafts. B, D, Vehicle-
treated grafts. A, B, Elastica van Gieson–stained sections; C, D,
Immunostaining for TN-C. In the cilostazol-treated graft body,
neointimal hyperplasia was markedly inhibited and TN-C–posi-
tive staining was observed in only a small portion of the media.
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PEffect of Cilostazol on TN-C Synthesis in SMCs
To determine whether cilostazol affects TN-C synthesis in
SMCs, we investigated TN-C mRNA expression in cultured
SMCs isolated from rat aorta. The addition of PDGF-BB
increased TN-C mRNA levels 3-fold in comparison with the
control. However, the addition of cilostazol (10 mol/L)
almost completely suppressed the up-regulation induced by
PDGF-BB (Figure 6).
Discussion
In this study, we established a new model of free artery graft
stenosis in rats based on the premise of free artery grafts in
coronary artery bypass grafting. After distal anastomotic
stricture, neointimal hyperplasia progressed rapidly in both
the graft body and anastomotic site. Furthermore, an in-
crease in PCNA index was also seen in the neointima of the
implanted grafts. Distal anastomotic stricture produces
blood turbulence or shear stress in grafts, which possibly
could induce certain factors for stimulating SMC prolifera-
tion and migration and result in neointimal hyperplasia.
Cilostazol is a specific inhibitor of cAMP phosphodies-
terase III that is clinically used for the treatment of periph-
eral arterial occlusive disease by oral delivery.25 Cilostazol
inhibits PDGF-induced SMC proliferation.21 It was reported
that systemic administration of cilostazol at 30 mg/kg by
mouth twice per day inhibited neointimal formation in bal-
loon-injured rat carotid artery by 32%.26 In addition, local
administration of cilostazol using Pluronic gel maintained a
high concentration of the drug at the application site and
suppressed neointimal formation through the direct inhibi-
tion of SMC proliferation in balloon-injured rat carotid
artery.18 Therefore, we examined the effect of cilostazol
applied locally to implanted artery grafts in suppressing
neointimal hyperplasia in our rat model. Topical application
of cilostazol to the implanted graft decreased the neointima/
media area ratio to as low as 1/7 in the graft body and to as
low as 1/4 at the anastomotic stricture site compared with
the vehicle-treated control. PCNA index was also decreased
to 1/10 in the graft body and to 1/2 in the stenotic site of the
anastomosis. These results indicate that cilostazol inhibits
neointimal hyperplasia at least partly by inhibiting cell
proliferation in the neointima.
ECM proteins play a crucial role in the remodeling of
blood vessels by their effects on cell adhesion, growth,
migration, and apoptosis.27 TN-C, an ECM protein, is im-
plicated in the activation of cell migration from the media to
the intima in vascular lesions.14 In fact, marked TN-C
expression is found in the restenotic neointima in the early
stage after PTCA, when cells most actively migrate from the
media to the neointima.13 In the present study, we observed
a high level of TN-C expression in the neointima of control
grafts but little expression in cilostazol-treated grafts. Sup-
The Journal of Thoracipression of TN-C synthesis seems to be another mechanism
behind the effect of cilostazol.
The results of previous in vitro studies demonstrated that
PDGF-BB is a powerful stimulator of TN-C expression in
SMCs.14 Therefore, we examined the effects of cilostazol
on TN-C expression in cultured SMCs after treatment with
PDGF-BB. The increased TN-C mRNA expression induced
by PDGF-BB was completely inhibited by the addition of
cilostazol.
It has been shown that the cAMP-protein kinase A signal
pathway inhibits the transmission of Ras signals from the
plasma membrane by preventing the Ras-dependent activa-
tion of Raf-1, resulting in inhibition of mitogen-activated
protein kinase activation.28-30 Mitogen-activated protein ki-
nase phosphorylates a variety of regulatory proteins and
transcription factors that play important roles in cell migra-
tion, proliferation, and differentiation.31 Local administra-
tion of 8-bromoadenosine-3',5'-cAMP and phosphodiester-
ase-inhibitor drugs (aminophylline and amrinone) inhibits
neointimal formation in balloon-injured rat carotid artery.19
Therefore, the effect of local administration of cilostazol on
the inhibition of SMC proliferation and TN-C expression
could be explained by an increased level of cAMP in SMC.
A recent article demonstrated that adventitial myofibro-
blasts are the initial source of TN-C, which stimulates the
myofibroblasts themselves to migrate from the adventitia to
the intima, and that migration is responsible for the progres-
32
Figure 5. Effect of cilostazol in inhibiting neointimal hyperplasia
in artery grafts at POD 28. A, B, Neointima/media area ratio. C, D,
PCNA index. A, C, Graft body. B, D, Distal anastomotic site. Four
sections per animal were selected, and data are mean  SD of
neointima/media area ratio and PCNA index from 5 animals per
group. Significant differences were seen between the cilostazol-
treated and vehicle-treated groups (*P < .05).sion of vascular remodeling. In the present study, using in
c and Cardiovascular Surgery ● Volume 128, Number 3 361
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initially localized in the adventitia and media but move to
the intima during neointimal formation. It seems that the
adventitia may be the primary site for vascular remodeling.
Therefore, the direct administration of a drug to the adven-
titia could be dramatically effective in preventing stenosis
of free artery grafts. The dramatic inhibitory effect of local
administration of cilostazol on intimal hyperplasia can be
attributed to the drug’s contribution to the adventitial re-
modeling of artery grafts. In addition, there is the possibility
that the other effects of the drug, antithrombotic and vaso-
dilatory effects, contribute to vascular remodeling.
The potential for clinical use of cilostazol on implanted
artery grafts in vascular surgery warrants further investiga-
tion.
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